1. Home
  2. CELU vs KYNB Comparison

CELU vs KYNB Comparison

Compare CELU & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.28

Market Cap

34.5M

Sector

Health Care

ML Signal

HOLD

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$7.33

Market Cap

31.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CELU
KYNB
Founded
2016
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.5M
31.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CELU
KYNB
Price
$1.28
$7.33
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
31.7K
30.9K
Earning Date
11-14-2025
03-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
53.38
Revenue
$40,578,000.00
$8,298,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$76.00
N/A
P/E Ratio
N/A
$0.14
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$4.85
52 Week High
$4.35
$21.94

Technical Indicators

Market Signals
Indicator
CELU
KYNB
Relative Strength Index (RSI) 49.25 36.71
Support Level $1.20 $7.32
Resistance Level $1.31 $8.25
Average True Range (ATR) 0.07 0.67
MACD 0.01 -0.06
Stochastic Oscillator 68.75 15.80

Price Performance

Historical Comparison
CELU
KYNB

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: